Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA

Haematologica

Volumn 96, Issue 12, 2011, Pages 1799-1807

  Schnittger, Susanne ^a   Bacher, Ulrike ^b   Haferlach, Claudia ^a   Kern, Wolfgang ^a   Alpermann, Tamara ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Acute promyelocytic leukemia; Additional chromosomal alterations; FLT3 mutations; FLT3 ITD wt ratio; Prognosis

Indexed keywords

CD135 ANTIGEN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN TYROSINE KINASE; RETINOIC ACID RECEPTOR ALPHA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE DUPLICATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROTEIN DOMAIN; SEX DIFFERENCE; SURVIVAL RATE; WILD TYPE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; SURVIVAL RATE; TRANSLOCATION, GENETIC; TRETINOIN;

EID: 82855164008     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049007     Document Type: Article

References (36)

1. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875-91.
2. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128-34.
3. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248-54.
4. Sanz MA, Lo Coco F., Martin G, Avvisati G, Rayon C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4): 1247-53.
5. Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12):2248-58.
6. Ades L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French- Belgian-Swiss and PETHEMA results. Blood. 2008;111(3):1078-84.
7. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011;29(5):495-503.
8. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73(5):1116-22.
9. Bassan R, Battista R, Viero P, d'Emilio A, Buelli M, Montaldi A, et al. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia. 1995;9(2):238-43.
10. Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J., Bennett JM, et al. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 2010; 116(25):5650-9.
11. Kuchenbauer F, Schoch C, Kern W, Hiddemann W, Haferlach T, Schnittger S. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol. 2005;130 (2):196-202.
12. Beitinjaneh A, Jang S, Roukoz H, Majhail NS. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;34(7):831-6.
13. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11(9):1447-52.
14. Kainz B, Heintel D, Marculescu R, Schwarzinger I, Sperr W, Le T, et al. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J. 2002;3(6):283-9.
15. Arber B, Brunning R, Le Beau M, Falini B. Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow S, Campo E, Lee Harris N, Jaffe E, Pileri S, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press, 2008:110-23.
16. Chillon MC, Santamaria C, Garcia-Sanz R, Balanzategui A, Maria ES, Alcoceba M, et al. Long FLT3 internal tandem duplications and reduced PML-RARalpha expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematologica. 2010;95(5):745-51.
17. Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716-25.
18. Löffler H, Raststetter J, Haferlach T. Atlas of Clinical Hematology, 6th ed. Berlin: Springer, 2004.
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-5.
20. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16(1):53-9.
21. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PMLRARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003;102(8):2746-55.
22. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-35.
23. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood. 2008;111(5):2527-37.
24. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104 (10):3078-85.
25. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia. 2011; 25(8):1297-304.
26. Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, et al. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997;15(5):1786-95.
27. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous alltrans-retinoic acid and chemotherapy. J Clin Oncol. 2000;18(6):1295-300.
28. Montesinos P, Rayon C, Vellenga E, Brunet S, Gonzalez J, Gonzalez M, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2011;117(6): 1799-805.
29. Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768-76.
30. Noguera NI, Breccia M, Divona M, Diverio D, Costa V, De Santis S., et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002;16(11):2185-9.
31. Au WY, Fung A, Chim CS, Lie AK, Liang R, Ma ES, et al. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol. 2004;125(4):463-9.
32. de Botton S., Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111 (3):801-6.
33. Cervera J, Montesinos P, Hernandez-Rivas JM, Calasanz MJ, Aventin A, Ferro MT, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010; 95(3):424-31.
34. Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol. 1996;94(3):493-500.
35. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, et al. Therapyrelated acute promyelocytic leukemia. J Clin Oncol. 2003;21(11):2123-37.
36. Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011; 117(7):2137-45.